Human papillomavirus 11 (HPV11) is a low‑risk type of human papillomavirus that infects mucosal and cutaneous epithelium. It is best known for causing anogenital warts and laryngeal papillomatosis and is part of the Papillomaviridae family of circular double‑stranded DNA viruses.
Virology and Pathogenesis
HPV11 belongs to the alpha group of papillomaviruses and has a circular double‑stranded DNA genome of about 8 kb organized into early (E) and late (L) open reading frames. The early region encodes proteins involved in replication and modulation of the host cell cycle, including E1, E2, E4, E5, E6 and E7, while the late region encodes the capsid proteins L1 and L2. Infection occurs via microtraumas that expose the basal keratinocytes of stratified squamous epithelium. The viral genome remains episomal and replication is tied to epithelial differentiation. HPV11 E6 and E7 proteins have weak affinity for p53 and retinoblastoma protein, so they do not efficiently disrupt cell cycle checkpoints, and lesions remain benign. The incubation period ranges from weeks to months, and infection leads to hyperproliferation and thickening of the epithelium. Most infections are cleared within two years, but persistence can occur, particularly in immunocompromised individuals. The virus can evade host immunity by reducing interferon responses and antigen presentation, and cell‑mediated immunity is critical for clearance. HPV11 spreads primarily through sexual contact or vertical transmission during childbirth. Because of its low oncogenic potential, routine HPV screening tests do not target HPV11, but it is included in quadrivalent and nonavalent vaccines to prevent wart formation.
Associated Conditions and Prevention
HPV11, together with HPV6, is responsible for the vast majority of anogenital warts. These lesions range from small flat papules to large exophytic masses on the vulva, vagina, penis, scrotum, urethra or perianal skin. They are often asymptomatic but can cause itching, discomfort or bleeding. Management includes patient‑applied therapies such as imiquimod cream and clinician‑administered therapies such as cryotherapy, electrosurgery or surgical excision. HPV11 is also a major cause of recurrent respiratory papillomatosis, a rare disease characterised by multiple papillomas of the larynx and airway that can lead to hoarseness and airway obstruction. Juvenile‑onset cases result from vertical transmission during childbirth, while adult‑onset cases are usually sexually acquired. Rarely, HPV11 has been detected in low‑grade cervical lesions, but it is not a major contributor to cervical cancer. Prophylactic vaccines containing the L1 protein of HPV11 provide protection against genital warts and are widely recommended for adolescents. Barrier methods such as condoms reduce transmission but do not eliminate risk. Because infection with one HPV type does not confer immunity to others, vaccination remains the most effective preventive tool. HPV11 is a low‑risk papillomavirus that causes benign mucocutaneous lesions, particularly genital warts and recurrent respiratory papillomatosis. Its genome replicates episomally and its proteins have limited oncogenic activity, so cancer development is rare. Vaccination and treatment of lesions help reduce the burden of HPV11 infection. Related Terms: Papillomaviridae, Anogenital warts, Recurrent respiratory papillomatosis, Low-risk HPV, HPV6